Join
Live feed
·
INSIDERFilingvia Quantisnow
Atrium Therapeutics Inc. logo

Chief Program Officer Gallagher Kathleen P. sold $8,915 worth of shares (188 units at $47.42), decreasing direct ownership by 0.37% to 50,204 units (SEC Form 4)

ByQuantisnow·Wall Street's wire, on your screen.
RNA· Atrium Therapeutics Inc.
Health Care
Original source

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track RNA (Atrium Therapeutics Inc.) and more on Quantisnow.